Suppr超能文献

腺病毒载体疫苗诱导的 CD8+ T 细胞能够预防潜伏性小鼠γ疱疹病毒 68 的感染。

CD8+ T cells induced by adenovirus-vectored vaccine are capable of preventing establishment of latent murine γ-herpesvirus 68 infection.

机构信息

Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Denmark; InProTher ApS, DK2200 Copenhagen, Denmark.

Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Denmark; NIA, NIH, Baltimore MD, USA.

出版信息

Vaccine. 2019 May 16;37(22):2952-2959. doi: 10.1016/j.vaccine.2019.04.034. Epub 2019 Apr 18.

Abstract

CD8+ T cells are known to control infections, but their role in preventing latent infection from establishing has not been thoroughly investigated. We hypothesized that a potent CD8+ T cell response patrolling the mucosal viral entry points could kill the first infected cells and thereby abrogate the infection before latency is established. To investigate this, replication deficient adenovirus serotype 5 vectors encoding murine γ-herpesvirus-68 CD8+ T cell epitopes linkedto the T cell adjuvant Invariant chain, were developed. We show that intranasal vaccination of mice reduces the risk of establishment of latent infection from multiple intranasal ID50 challenges with murine γ-herpesvirus-68 by 81% per exposure at 14 days post vaccination. Protection waned over time, but immune responses were extended by heterologous prime-boost vaccination applied simultaneously intramuscularly and intranasally, and animals vaccinated 66 days prior to challenge showed a strong trend of long-term protection. Our data provides evidence that CD8+ T cells are able to protect against establishment of latent infection. Although the protective efficacy is difficult to maintain over time, this proof-of-concept study suggests a role for a CD8+ T cell arm in future vaccine strategies against latent human viral infections caused by pathogens such as HIV and multiple herpes virus.

摘要

CD8+ T 细胞被认为可以控制感染,但它们在防止潜伏感染方面的作用尚未得到彻底研究。我们假设,在潜伏感染建立之前,一种强大的 CD8+ T 细胞反应可以在黏膜病毒进入点巡逻,杀死第一个受感染的细胞,从而阻断感染。为了研究这一点,我们开发了复制缺陷型腺病毒血清型 5 载体,编码与 T 细胞佐剂不变链相连的小鼠γ疱疹病毒-68 CD8+ T 细胞表位。我们发现,鼻腔接种疫苗可使小鼠在 14 天接种后,每暴露一次,就能将潜伏感染建立的风险降低 81%,其效价为 50%。保护作用随时间减弱,但通过同时肌肉内和鼻腔内接种异源初免-加强疫苗,可延长免疫反应,而在挑战前 66 天接种疫苗的动物则显示出长期保护的强烈趋势。我们的数据提供了证据表明,CD8+ T 细胞能够防止潜伏感染的建立。尽管保护效果很难随时间维持,但这项概念验证研究表明,针对 HIV 和多种疱疹病毒等病原体引起的潜伏性人类病毒感染,CD8+ T 细胞可能在未来的疫苗策略中发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验